Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor
Infect Dis Ther
.
2024 Sep;13(9):2103.
doi: 10.1007/s40121-024-01030-0.
Authors
Takayuki Katsube
1
,
Safwan Kezbor
2
,
Ryosuke Shimizu
3
,
Ryuji Kubota
3
Affiliations
1
Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-Ku, Osaka, 541-0042, Japan. takayuki.katsube@shionogi.co.jp.
2
Shionogi Inc., 400 Campus Drive, 4th Fl., Florham Park, NJ, 07932, USA.
3
Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-Ku, Osaka, 541-0042, Japan.
PMID:
39136875
PMCID:
PMC11343925
DOI:
10.1007/s40121-024-01030-0
No abstract available
Publication types
Published Erratum